← Patent-cliff monitor small molecule ISTURISA OSILODROSTAT PHOSPHATE
Loss of exclusivity October 2035 latest FDA-listed patent expiry
Drug detail Brand name ISTURISA Active ingredient OSILODROSTAT PHOSPHATE Strength EQ 1MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval March 2020 Marketing status RX
Listed patents Patent Expires Type 10709691 October 2035 use U-4529 10143680 July 2035 product 8314097 May 2033 substance, product 8609862 January 2031 use U-4529 9434754 January 2031 substance 8835646 August 2026 substance, product
Regulatory exclusivity Code Expires ODE-535 April 2032 ODE-286 March 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.